key: cord-0994265-qs6dwip3
authors: Sajid, Mir Ibrahim; Najaf, Dur‐E.; Niaz, Ayesha; Shabbir Balouch, Samira; Abaidullah, Sajid
title: SARS‐CoV‐2 & androgenic alopecia: exploring links!
date: 2021-01-31
journal: Int J Dermatol
DOI: 10.1111/ijd.15410
sha: 806ccb11d3dca7bb800a66ce0a5ca8d80d18afa3
doc_id: 994265
cord_uid: qs6dwip3

nan

resulting in the reduction of the anagen phase. 1 SARS-CoV-2 has shown a spectrum of clinical dermatological manifestations, in both hospitalized and nonhospitalized patients, androgenetic alopecia areata (AA) being a predominant presentation. 2 The viral disease is dependent on the binding of viral spike (S) protein to the angiotensin-converting enzyme 2 (ACE-2) and transmembrane protease serine 2 (TMPRSS2)-mediated cleavage of the S-protein resulting in viro-cellular membrane fusion, and entry of the virus into the host cell. 3 Moreover, TMPRSS2 activity has shown to cleave ACE-2, augmenting the viral entry of SARS-CoV-1. Studies have shown that only androgen receptor activity is required for the transcription and regulation of TMPRSS2 in nonprostatic tissues including the lung and scalp. 3 With an underlying pathophysiological explanation, the observations of an increased incidence of AA globally linked to SARS-CoV-2 became evident. Kutlu 

Potential targets in the discovery of new hair growth promoters for androgenic alopecia

Androgen sensitivity gateway to COVID-19 disease severity

Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532)

Short-term stress-related increasing cases of alopecia areata during the COVID-19 pandemic

A preliminary observation: Male pattern hair loss among hospitalized COVID-19 patients in Spain-A potential clue to the role of androgens in COVID-19 severity

An Antiandrogenic and Anti-hypertensive Drug That May Provide Protection Against the Novel Coronavirus (SARS-CoV-2) Induced Acute Respiratory Distress Syndrome (ARDS) in COVID-19

Cepharanthine: a review of the antiviral potential of a Japanese-approved alopecia drug in COVID-19

Androgenetic alopecia present in the majority of patients hospitalized with COVID-19: The "Gabrin sign

Evaluation of the effects of COVID-19 pandemic on hair diseases through a web-based questionnaire